文献速递免疫规划卫生政策与健康促进

中国50岁及以上成人重组带状疱疹疫苗的成本效益

Cost-Effectiveness of Recombinant Zoster Vaccine for Adults Aged ≥50 Years in China.
PubMed 文献 · Am J Prev Med · 2023-05-12

该研究构建终身马尔可夫模型,从社会视角比较重组带状疱疹疫苗(RZV)与不接种的经济学与健康影响。RZV可避免大量带状疱疹及并发症病例,但增量成本效益比在34465.5至51002.7美元/质量调整生命年之间,在60-69岁人群中成本效益概率较高。

要点

  • RZV可避免1893530例带状疱疹、295761例带状疱疹后神经痛及229例相关死亡。
  • 以三倍人均GDP为支付意愿阈值时,60-69岁人群成本效益概率为59.32%。

核心结论

  • RZV在60-69岁人群中很可能具有成本效益,疫苗成本小幅下降可使所有50岁及以上人群具有成本效益。

研究设计与样本

  • 研究构建终身马尔可夫模型,从社会视角比较RZV与不接种的成本效益,模型输入来自已发表文献,分析于2022年进行。

主要发现

  • RZV的增量成本效益比在34465.5至51002.7美元/质量调整生命年之间。
  • 当贴现率低于2.4%、2剂RZV效力衰减率降至低于0.8%、带状疱疹后神经痛效用值低于0.496、带状疱疹后神经痛持续时间超过12.86个月或RZV每剂成本降至低于229.6美元时,RZV对整个队列具有成本效益。
  • 以三倍人均GDP(37654.5美元/质量调整生命年)为支付意愿阈值,概率敏感性分析中RZV具有成本效益的概率在50-59岁、60-69岁、70-79岁和80岁及以上人群分别为43.95%、59.32%、45.27%和39.50%。

关键数值与推荐

  • 增量成本效益比范围为34465.5至51002.7美元/质量调整生命年。
  • 成本效益概率:50-59岁43.95%,60-69岁59.32%,70-79岁45.27%,80岁及以上39.50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adjuvanted recombinant zoster vaccine (RZV) was the first vaccine made available for herpes zoster in China. Authors aimed to evaluate its economic and health impacts on Chinese adults aged ≥50 years. METHODS: A lifetime Markov model was developed to compare the cost-effectiveness of RZV with that of no vaccination from a societal perspective. Model inputs were derived from published literature and analyzed in 2022. Outcomes included total costs, quality-adjusted life-years, incremental cost-effectiveness ratio, and number of herpes zoster and herpes zoster-related cases. Sensitivity analyses were performed to examine the robustness of the model results. RESULTS: RZV was more costly than no vaccination by $2.78 billion with an additional 65,008 quality-adjusted life-years gained and could avoid 1,893,530 herpes zoster cases, 295,761 postherpetic neuralgia cases, 51,734 other complications, and 229 herpes zoster-related deaths. Incremental cost-effectiveness ratios of RZV varied in a range of $34,465.5-$51,002.7 per quality-adjusted life-year. RZV for the entire cohort would be cost-effective when discount rate was <2.4%, a waning rate of 2-dose RZV efficacy decreased to <0.8%, the utility of postherpetic neuralgia was <0.496, duration of postherpetic neuralgia was >12.86 months, or the cost of RZV per dose decreased to <$229.6. In a probabilistic sensitivity analysis, the probability of RZV being cost-effective was 43.95%, 59.32%, 45.27%, and 39.50% for people aged 50-59, 60-69, 70-79, and ≥80 years, respectively, with threefold gross domestic product per capita (37,654.5 per quality-adjusted life-year) as the willingness-to-pay threshold. CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Jiang M, Yao X, Peng J, et al. Cost-Effectiveness of Recombinant Zoster Vaccine for Adults Aged ≥50 Years in China. Am J Prev Med. 2023. PMID: 37182556. doi:10.1016/j.amepre.2023.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。